Tenaya Therapeutics Inc. TNYA on Friday reported interim Phase 1b/2 RIDGE-1 data showing its TN-401 gene therapy reduced ...
All Patients Achieved Meaningful Decreases (Mean = 64%) in Daily Premature Ventricular Contraction Count TN-401 Gene Therapy ...
Here at Men's Journal, our team of editors and writers are constantly testing the latest gear and cool gadgets to find the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results